CLDN6 and breast cancer: Because CLDN6 attenuates hypoxia-induced tumour metastasis in a SUMOylation-dependent manner, these findings might provide a novel strategy for breast cancer treatment, and directly targeting SENP1/HIF-1α might prove to be a beneficial anti-cancer therapy.